Company intelligence / Profile preview

Constructive Bio

Cambridge / Whittlesford, England, United Kingdomconstructive.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

No clinical results reported; company’s focus remains on developing its synthetic genomics platform, demonstrating proof-of-concept in whole-genome rewriting, phage resistance, and programmable biomanufacturing.

Therapeutic areas: Other
Modalities: Programmable biomolecules (including non-canonical amino acid incorporation)Engineered proteins/biopolymers
Industry: Non-Drug Biotech

Partnerships

Investors include Ahren Innovation Capital, OMX Ventures, ND Capital (+ND), Fine Structure Ventures, Paladin Capital Group among others.

Beyond the preview

Go deeper on Constructive Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Constructive Bio.

Explore the full profile